Neo Ivy Capital Management Gilead Sciences, Inc. Transaction History

Neo Ivy Capital Management

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$57.72 - $65.01 $157,344 - $177,217	-2,726 Reduced 66.85%	1,352 $83,000
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $236,197 - $295,981	4,078 New	4,078 $242,000
Q4 2021 Feb 15, 2022	SELL	$64.88 - $73.64 $62,998 - $71,504	-971 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$67.69 - $73.03 $65,726 - $70,912	971 New	971 $75,000
Q2 2021 Aug 16, 2021	SELL	$63.47 - $69.35 $230,142 - $251,463	-3,626 Closed	0 $0
Q1 2021 Oct 07, 2021	SELL	$60.0 - $68.46 $308,460 - $351,952	-5,141 Reduced 58.64%	3,626 $234,000
Q4 2020 Feb 16, 2021	BUY	$56.65 - $64.55 $496,650 - $565,909	8,767 New	8,767 $511,000
Q2 2020 Aug 17, 2020	SELL	$72.34 - $84.0 $70,242 - $81,564	-971 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$72.34 - $84.0 $54,182 - $62,916	749 Added 337.39%	971 $75,000
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $663,940 - $850,412	-10,601 Reduced 97.95%	222 $17,000
Q4 2019 Feb 13, 2020	BUY	$61.62 - $67.78 $45,044 - $49,547	731 Added 7.24%	10,823 $703,000
Q3 2019 Nov 21, 2019	BUY	$62.51 - $69.0 $630,850 - $696,348	10,092 New	10,092 $641,000
Q1 2019 May 15, 2019	SELL	$62.53 - $70.05 $1.12 Million - $1.26 Million	-17,984 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$60.54 - $79.0 $1.09 Million - $1.42 Million	17,984 New	17,984 $1.13 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.